Cover Image
市場調查報告書

Chong Kun Dang Pharmaceutical Corp.:產品平台分析

Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224658
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
Chong Kun Dang Pharmaceutical Corp.:產品平台分析 Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 63 Pages
簡介

Chong Kun Dang Pharmaceutical Corp.是從事以散裝藥為首,處方藥,成藥,還有維他命,洗髮精,染髮劑,氣霧劑,香片汽化器,蚊香等產品之批發及進出口的製藥公司。該公司的中央研究所更致力於腫瘤學,免疫學,心血管,代謝性疾病,感染疾病、中樞神經系統疾病,呼吸疾病領域治療藥之研究,化學性研究,及新藥的開發。

本報告提供Chong Kun Dang Pharmaceutical Corp.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Chong Kun Dang Pharmaceutical Corp.的基本資料

Chong Kun Dang Pharmaceutical Corp.概要

  • 主要資訊
  • 企業資料

Chong Kun Dang Pharmaceutical Corp. :R&D概要

  • 主要的治療範圍

Chong Kun Dang Pharmaceutical Corp. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Chong Kun Dang Pharmaceutical Corp. :開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Chong Kun Dang Pharmaceutical Corp. :藥物簡介

  • beloranib
  • carvedilol SR
  • CKD-943
  • (amlodipine besylate + candesartan)
  • CKD-941
  • CKD-942
  • CR-845
  • LT-0011
  • CKD-12101
  • CKD-12201
  • CKD-516
  • CKD-519
  • CKD-581
  • CKD-902
  • CKD-903
  • darbepoetin alfa
  • CKD-10101
  • CKD-830
  • CKD-841
  • Drug to Inhibit HDAC6 for Rheumatoid Arthritis
  • Nepodin

Chong Kun Dang Pharmaceutical Corp. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Chong Kun Dang Pharmaceutical Corp. :最近的開發平台趨勢

Chong Kun Dang Pharmaceutical Corp. :暫停中的計劃

Chong Kun Dang Pharmaceutical Corp. :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08200CDB

Summary

Global Markets Direct's, 'Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016', provides an overview of the Chong Kun Dang Pharmaceutical Corp's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Chong Kun Dang Pharmaceutical Corp
  • The report provides overview of Chong Kun Dang Pharmaceutical Corp including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chong Kun Dang Pharmaceutical Corp's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chong Kun Dang Pharmaceutical Corp's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Chong Kun Dang Pharmaceutical Corp's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chong Kun Dang Pharmaceutical Corp
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chong Kun Dang Pharmaceutical Corp's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chong Kun Dang Pharmaceutical Corp Snapshot
    • Chong Kun Dang Pharmaceutical Corp Overview
    • Key Facts
  • Chong Kun Dang Pharmaceutical Corp - Research and Development Overview
    • Key Therapeutic Areas
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products Glance
    • Chong Kun Dang Pharmaceutical Corp - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chong Kun Dang Pharmaceutical Corp - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chong Kun Dang Pharmaceutical Corp - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Chong Kun Dang Pharmaceutical Corp - Drug Profiles
    • (amlodipine besylate + candesartan cilexetil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (atorvastatin calcium + choline fenofibrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (atorvastatin calcium + ezetimibe) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lobeglitazone + metformin hydrochloride XR) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (tadalafil + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-516 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-581 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • difelikefalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hyaluronate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levocabastine hydrochloride + mometasone furoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nepodin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Analysis
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Target
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Route of Administration
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Molecule Type
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action
  • Chong Kun Dang Pharmaceutical Corp - Dormant Projects
  • Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • beloranib
  • Chong Kun Dang Pharmaceutical Corp - Company Statement
  • Chong Kun Dang Pharmaceutical Corp - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chong Kun Dang Pharmaceutical Corp, Key Facts
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Indication, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
  • Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Combination Treatment Modalities in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase III, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase II, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase I, 2016
  • Chong Kun Dang Pharmaceutical Corp - Preclinical, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Target, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action, 2016
  • Chong Kun Dang Pharmaceutical Corp - Dormant Developmental Projects,2016
  • Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products, 2016
  • Chong Kun Dang Pharmaceutical Corp, Other Locations

List of Figures

  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Indication, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
  • Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Target, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top